

# JINARC Patient-Prescriber Agreement Form (PPAF)

Please return this completed and signed PPAF by fax to: **1-844-3JINARC (354-6272)**.

**PRESCRIBER  
SECTION**

Pr JINARC® (tolvaptan) is available in Canada. **JINARC can only be prescribed to patients who have completed and signed this form with their prescriber.**

The purpose of this Patient-Prescriber Agreement Form (PPAF) is to document the fully-considered engagement of both the patient and the prescriber to the treatment of autosomal dominant polycystic kidney disease (ADPKD) with JINARC ("Product"). In accordance with Health Canada requirements, the manufacturer of JINARC has implemented a safety monitoring initiative with regard to use of and access to JINARC. This initial step will also serve to confirm the patient enrollment into the JINARC Controlled Hepatic Safety Monitoring and Distribution Programme ("Programme"). The manufacturer of JINARC is Otsuka Canada Pharmaceutical Inc. ("Otsuka"). Otsuka is responsible for the Programme and may administer, in whole or in part with a designated third-party service provider, the Programme.

JINARC is indicated to slow the progression of kidney enlargement and kidney function decline in patients with ADPKD. In ADPKD, kidney enlargement reflects renal cyst burden.

Careful consideration and discussion of the appropriateness of JINARC treatment should be undertaken between the prescriber and patient before initiation of treatment, taking into account the potential benefits and risks of treatment, appropriate patient selection, and the need for mandatory ongoing hepatic function monitoring.

Following mutual agreement to undertake treatment with JINARC, both the patient and their prescriber must complete, sign, and date this PPAF in person, together

at the same time. The patient and prescriber must read each statement of their respective section(s) of this PPAF thoroughly, **add their initials before each statement** confirming that he/she understands the benefits and risks of treatment with JINARC and agrees to comply with the conditions for use prior to initiating JINARC.

**Please return all pages of this completed and signed PPAF by fax to: 1-844-3JINARC (354-6272).** Incomplete information will result in delay. Please call **1-844-2JINARC (254-6272)** if you have any questions regarding the Programme. A Programme nurse will contact the patient to acknowledge and confirm enrollment if the patient provides the required consent as specifically set out herein.

JINARC is only distributed to pharmacies through a unique distributor who will verify with the Programme that there is a signed and valid PPAF on file prior to distributing JINARC. **To allow the Programme specialty pharmacy to dispense JINARC, the prescriber should complete the prescription information section on this form.**

Both the patient and prescriber should keep a copy of the executed PPAF for their records. Should the patient's attending prescriber change, this PPAF will need to be renewed. In the event that there are material changes to the Programme, this PPAF or the Product Monograph for JINARC, the prescriber and the patient will be contacted and informed of such changes. The PPAF is specific to JINARC and cannot be used for any other product.

PRESCRIBER INITIALS	<p><b>As the PRESCRIBER of JINARC for the undersigned patient, I acknowledge that:</b></p> <p><input type="radio"/> I am a nephrologist or,  <input type="radio"/> I am a specialist experienced in the management of autosomal dominant polycystic kidney disease (ADPKD).                  Please provide a brief description of your experience/training: _____</p> <p>I understand that JINARC is indicated to slow the progression of kidney enlargement and kidney function decline in patients with ADPKD. In ADPKD, kidney enlargement reflects renal cyst burden.</p> <p>I understand that JINARC is contraindicated in patients: who have been asked to permanently discontinue tolvaptan in the past; with known or suspected hypersensitivity to tolvaptan, benzazepine or benzazepine derivatives (e.g., mirtazapine) or any of the excipients; with hypovolemia; with hypernatremia; with anuria; who do not have access to fluids or who cannot respond to the physiologic sensation of thirst; with a history, signs or symptoms of significant liver impairment or injury, excluding uncomplicated polycystic liver disease; who are using strong CYP3A inhibitors; who are pregnant or nursing; or who have one of the following rare hereditary diseases: Galactose intolerance, Lapp lactase deficiency or Glucose-galactose malabsorption.</p> <p>I understand that JINARC has not been studied in pediatric patients (&lt;18 years of age) with ADPKD. Its use is therefore not recommended in this patient population. Also, patients who are at, or approaching, end-stage renal disease, would not be expected to benefit from JINARC treatment.</p> <p>I understand that the patients most likely to benefit from JINARC treatment according to the TEMPO 3:4 trial, appear to be those with rapidly progressive ADPKD, or at a stage of incipient rapid progression, but before widespread destruction of renal architecture has occurred. Patients who are also likely to benefit from JINARC according to the REPRISÉ trial, appear to be those at high risk of progressive eGFR decline based on renal function for age (18 to 65 years of age with baseline eGFR between 25 and 65 mL/min/1.73m<sup>2</sup>). I will comply with patient selection criteria as outlined in the totality of the JINARC Product Monograph.</p> <p>I have reviewed and understood the risks and potential benefits of JINARC, as well as the requirements of the Hepatic Safety Monitoring and Distribution Programme.</p> <p>I have counselled my patient about the potential risks and benefits of JINARC, the criteria for selecting him/her for this treatment, the appropriate use of JINARC, as well as the need for mandatory ongoing hepatic function testing.</p> <p>I have provided and reviewed the mandatory JINARC patient educational material with my patient.</p> <p>I understand the Hepatic Safety Monitoring and Distribution Programme will send me a liver function status report form for every liver function test required of the patient. I further understand that I, or my delegate(s), must complete, sign and return this report to the Programme in order to ensure that the patient's pharmacy can continue to order and dispense JINARC to my patient. I acknowledge that failure to do so may lead to JINARC supply interruptions for this patient. I understand the Programme may contact me by phone, fax or by email after sending the liver function status report form to follow up on the availability of pending results for a given month or to provide me with information on the Programme.</p> <p>Prior to initiating and prescribing JINARC, I will confirm that my patient's liver function test (i.e., ALT and AST) levels are less than three (3) times the upper limit of normal, and total bilirubin has been assessed.</p> <p>I have reviewed the "Prescriber Privacy and Consent Declaration" on this form and I agree to its terms and conditions.</p>
------------------------	---

<p><b>Prescriber Information</b></p> <p style="font-size: 2em; color: #ccc; opacity: 0.5;">Prescriber Stamp</p> <p>First name: _____</p> <p>Last name: _____</p> <p>Medical license #: _____</p> <p>Email address: _____</p> <p>Telephone number: _____</p> <p>Fax number: _____</p> <p>Street address: _____</p> <p>City: _____</p> <p>Province: _____ Postal code: _____</p> <p>Primary office contact person name (if different):                  _____</p> <p>Telephone number: _____</p>		
<p><b>Prescription Information</b></p> <p>Patient first name: _____</p> <p>Patient last name: _____</p> <p><b>JINARC oral tablets:</b></p> <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <input type="radio"/> 45+15 mg (60 mg)  <input type="radio"/> 60+30 mg (90 mg)  <input type="radio"/> 90+30 mg (120 mg)                 </td> <td style="width: 50%; vertical-align: top;">                     One _____ mg tablet p.o. AM and one _____ mg tablet 8 hours later                      Disp: _____ weekly blister packs (14 tabs per pack)                      Refill x _____                 </td> </tr> </table> <p>This original prescription constitutes a legal prescription for the patient for JINARC. The original copy of this prescription will be kept in my files and will not be re-used. Completion of this section is required for medication to be dispensed.</p> <p>Signature: <b>X</b> _____</p> <p>Date: _____                  DD/MM/YYYY</p>	<input type="radio"/> 45+15 mg (60 mg) <input type="radio"/> 60+30 mg (90 mg) <input type="radio"/> 90+30 mg (120 mg)	One _____ mg tablet p.o. AM and one _____ mg tablet 8 hours later Disp: _____ weekly blister packs (14 tabs per pack) Refill x _____
<input type="radio"/> 45+15 mg (60 mg) <input type="radio"/> 60+30 mg (90 mg) <input type="radio"/> 90+30 mg (120 mg)	One _____ mg tablet p.o. AM and one _____ mg tablet 8 hours later Disp: _____ weekly blister packs (14 tabs per pack) Refill x _____	

The Programme is provided by Otsuka Canada Pharmaceutical Inc. (“Otsuka”) and may be administered, in whole or in part by Otsuka and a designated third-party service provider, McKesson Canada Corporation acting on its behalf and on behalf of its Specialty Health Division (collectively referred to as “McKesson Canada”). Otsuka and McKesson Canada (“Program Administrator”) respect all applicable privacy laws and as such have agreed that identifiable patient information will only be accessible by employees of the Program Administrator directly involved in the provision of the services and support to the Programme (“Programme Support Team”) or to any other third party if required by law or for safety information reporting unless specific consent has been obtained.

The Programme will limit data collection to information required for Programme administration. Generally accepted industry standards shall be used to store and protect confidential data, and access will be limited to the Programme Support Team.

The Program Administrator shall comply with and abide by all applicable privacy legislation in the jurisdictions in which the services for the Programme are to be provided and where the Programme information is stored. The Programme is only intended to provide support to your patients, to you (the Prescriber), and your treatment team so that you can best support patients that, in your professional judgement, would benefit from Pr JINARC®. The Programme is also there to ensure that you and your team have the support and knowledge you need about JINARC. The Programme is not intended to replace your professional judgement, or the professional judgement of other healthcare professionals involved in the patient’s care. As the Prescriber of JINARC, you are responsible for using your professional judgement regarding the use of the Programme tools and services.

By accepting participation in the Programme, as the Prescriber of JINARC for the undersigned patient, I understand and agree:

- (1) That I have received and reviewed the Product Monograph and I will undertake to use JINARC as clinically appropriate for the purpose of the Programme.
- (2) To provide cooperation and necessary information to facilitate all necessary steps for patients to be able to seek private or public coverage and ensure that any such requests are submitted in a timely fashion or are underway prior to requesting the medication supplied by the Programme.
- (3) To the collection, use and disclosure of information by the Program Administrator for the Programme to support its services and to meet Health Canada requirements for the Programme.
- (4) To the disclosure by the Program Administrator to Otsuka that I have enrolled to participate in the Programme.
- (5) To the disclosure by the Program Administrator to Otsuka personnel, not part of the Program Support Team of de-identified patient information, or as required, aggregated de-identified patient information (depending on the nature of the information) so as to not permit the identification of the patient, specifically: liver function test monitoring status, Product shipment history under the Programme, as well as high-level summary information including, but not limited to, size of Product patient population and those covered/non-covered by public or private plans.
- (6) That unless specific consent has been obtained, that email communication will not be used for the exchange of any patient personal information and/or health information.
- (7) To patient personal information and/or health information and/or adverse events being collected, viewed, stored and analyzed in or outside of Canada where we have facilities or in which we use third-party service providers. In that case, personal information will be subject to the laws of the country in which they are located and may be disclosed to governments, courts or law enforcement or regulatory agencies of that other country and in accordance with the laws of that other country, but the practices of the Program Administrator regarding my personal information will at all times be governed by this privacy policy.
- (8) That, should I report safety information (including adverse events) and Product quality complaints to the Programme, I acknowledge that this information will be reported by the Program Administrator to Otsuka during the course of the patient’s participation in the Programme. I also agree to be consulted to provide follow-up information, until such time as I explicitly inform Otsuka, in writing, of my desire not to be consulted. I acknowledge that such adverse event reports may need to be forwarded to regulatory authorities in and outside of Canada.
- (9) That in the event that Otsuka appoints a third-party service provider, other than McKesson Canada, for the administration of the Programme, in its entirety or for a specific service for or through the Programme, I agree to the transfer of this PPAF and information contained herein, or related thereto, to such third-party service provider under the same terms and conditions as set out herein.
- (10) That this PPAF is only applicable for treatment with JINARC.

I hereby confirm that I have read and understood the information provided and related to the Programme, and agree to participate as a Prescriber. I understand that I may suspend my participation in the Programme at any time. To do this, I must contact the Program Administrator at the number provided. I further understand that the Programme is mandated by Health Canada and if I suspend my participation, access to the Product may be terminated. I further understand that Otsuka reserves the right in their sole discretion to modify, suspend access to, or terminate the Programme.

# JINARC Patient-Prescriber Agreement Form (PPAF)

Please return this completed and signed PPAF by fax to: **1-844-3JINARC (354-6272)**.

PATIENT  
SECTION

PATIENT INITIALS	<b>As the PATIENT being prescribed <sup>Pr</sup> JINARC®, I acknowledge that:</b>
	I understand that JINARC is able to slow the growth of cysts in kidneys and the decline of kidney function. This should help protect my kidneys from damage and failure.
	My Prescriber has given me a copy of the mandatory patient educational material about JINARC and has reviewed it with me.
	I understand the risks, especially for the liver, and the benefits that may occur over time when receiving treatment with JINARC, as presented by my Prescriber.
	I understand that I must go for blood tests to check my liver function during JINARC treatment, as prescribed by my Prescriber: monthly for the first 18 months, every 3 months for the next 12 months, and then every 3-6 months thereafter.
	I understand that if I do not go for my blood tests, the Programme pharmacy will no longer be able to order and dispense JINARC for me, which could lead to treatment discontinuations or interruptions.
	I understand I should inform my Prescriber if I have symptoms like fatigue, loss of appetite, right upper abdominal discomfort, dark urine, or jaundice (yellowing of the eyes and skin).
	I should take this medicine every day exactly as my Prescriber has told me in order for JINARC to better protect my kidneys.
	I understand that my Prescriber may be invited to participate in a Canadian JINARC Patient Outcomes Registry (C-MAJOR) to measure the impact of JINARC on my kidneys and overall health over time and that I may be invited to participate by signing a separate consent form. In the case that I agree to participate, I understand that the data collected from this Hepatic Safety Monitoring and Distribution Programme ("Programme") will be transferred to the Registry, as appropriate.
	I have reviewed the "Patient Privacy and Consent Declaration" and I agree to its terms and conditions which allow my healthcare providers to share my health information, as defined in this document, to the Program Administrator, for the limited purpose of managing the JINARC Hepatic Safety Monitoring and Distribution Programme.

## Patient Information

Referred by:  Nephrologist  Family physician

First name: \_\_\_\_\_ Last name: \_\_\_\_\_

Date of birth: \_\_\_\_\_ Gender:  Male  Female Email address: \_\_\_\_\_  
DD/MM/YYYY

Mobile number: \_\_\_\_\_ Telephone number: \_\_\_\_\_

Street address: \_\_\_\_\_ City: \_\_\_\_\_ Province: \_\_\_\_\_ Postal code: \_\_\_\_\_

Name of your family physician:\* \_\_\_\_\_

Telephone number: \_\_\_\_\_ Fax number: \_\_\_\_\_

Street address: \_\_\_\_\_ City: \_\_\_\_\_ Province: \_\_\_\_\_ Postal code: \_\_\_\_\_

Name of your pharmacist:\* \_\_\_\_\_

Telephone number: \_\_\_\_\_ Fax number: \_\_\_\_\_

Street address: \_\_\_\_\_ City: \_\_\_\_\_ Province: \_\_\_\_\_ Postal code: \_\_\_\_\_

\* By providing us with the names of your family physician and your pharmacist, you are giving the Programme consent to inform them that you have been prescribed JINARC and to provide them with information on autosomal dominant polycystic kidney disease and JINARC.

- I have read and agree to the Patient Privacy and Consent Declaration on this form.
- By checking this box, I also agree to receive a "welcome call" from the Programme nurse to confirm my enrollment in the Programme, the Programme pharmacy and to introduce me to the ORIJIN® Patient Support Program which involves support to access reimbursement from my health insurance company, financial assistance (if and where required), access to a Programme nurse for counselling and other related services as they become available. All of which shall be subject to the same privacy consent granted on this form. I understand the Program Administrator may need to disclose my Personal Information to my insurers and my healthcare providers in order to provide me with such services.
- By checking this box, I agree to share my email address and first name with Otsuka, the makers of JINARC, for the purpose of receiving the ORIJIN Newsletter and other electronic communications from [jinarc.ca/support](http://jinarc.ca/support). I will have the opportunity to opt-out from such communications.

If you are unavailable, can the Programme leave you a message?  Yes  No Best time for contact:  Morning  Afternoon  Evening  No preference

Signature: **X** \_\_\_\_\_ Date: \_\_\_\_\_  
DD/MM/YYYY

The Programme is provided by Otsuka Canada Pharmaceutical Inc. (“Otsuka”) and may be administered, in whole or in part by Otsuka and a designated third-party service provider, McKesson Canada Corporation acting on its behalf and on behalf of its Specialty Health Division (collectively referred to as “McKesson Canada”). Otsuka and McKesson Canada (“Program Administrator”) respect all applicable privacy laws and as such have agreed that identifiable patient information will only be accessible by employees of the Program Administrator directly involved in the provision of the services and support to the Programme (“Programme Support Team”) or to any other third party if required by law or for safety information reporting unless specific consent has been obtained.

I have been informed by my healthcare provider of the Programme purpose and have been given the opportunity to discuss this Programme with my healthcare provider. I understand that it is my right to refuse to sign this consent form. By signing the consent, I acknowledge my agreement to enroll in the Programme.

I authorize my Prescriber and his/her staff, and my health insurer(s) to disclose my personal information, including information about my insurance, prescriptions, verifying or coordinating insurance coverage(s), medication delivery and compliance, medical condition and health (“Personal Information”) to the Programme Support Team for the purposes of the Programme and as otherwise permitted or required under law. I am aware the Programme Support Team adheres to a strict privacy policy.

My Personal Information will be retained only as long as necessary for the fulfilment of the purposes for which it was collected and/or for which consent was received, unless otherwise required by law. My Personal Information that is no longer required to fulfil the identified purposes will be destroyed, erased or made anonymous.

I also authorize my healthcare provider to provide the Program Administrator with this completed Patient-Prescriber Agreement Form (“PPAF”) on my behalf so that the Programme Support Team can contact me in connection with the Programme. I acknowledge that I am responsible for any charges by my cell phone provider, should I choose to be contacted on my cell phone.

I authorize Otsuka personnel, not part of the Programme Support Team, to collect unidentifiable aggregate data for Programme management purposes. Unidentifiable aggregate data may be used for publication relating to the Programme; however, my Personal Information will not be used or disclosed for any purpose other than as described above. All information collected will be archived by the Program Administrator. If an adverse event is disclosed by me and/or about my state of health through the Programme, such information will be conveyed to Otsuka, with my initials (and date of birth and/or gender, if known), so that Otsuka can follow up with my Prescriber appropriately. This is necessary for Otsuka to maintain the most up-to-date records as to the safety profile of its products.

I consent to my Personal Information and any information relating to adverse events reporting being collected, viewed, stored and analyzed in or outside of Canada where we have facilities or in which we use third-party service providers. In that case, my Personal Information will be subject to the laws of the country in which they are located and may be disclosed to governments, courts or law enforcement or regulatory agencies of that other country and in accordance with the laws of that other country, but the practices of the Program Administrator regarding my Personal information will at all times be governed by this privacy policy.

I understand that I have the right to revoke this consent at any time by contacting the Programme at 1-844-2JINARC (1-844-254-6272); however, information about me already collected and disclosed for the purposes of the Programme will not be destroyed, except under those exceptions specified by law. I may arrange a right of access to the information held by the Program Administrator and may rectify deficient information. I acknowledge that revocation of consent may prevent my continued participation in the Programme.

In the event that Otsuka appoints a third-party service provider, other than McKesson Canada, for the administration of the Programme in its entirety or for a specific service provided for or through the Programme, I agree to the transfer of all my Personal Information and services to such third-party service provider under the same terms and conditions as set out herein.

Since <sup>Pr</sup> JINARC<sup>®</sup> can only be sold to pharmacies by a unique distributor (McKesson Canada), I authorize the Programme pharmacy to contact if needed my pharmacy (indicated on this form or that I will have communicated to the Programme) to exchange information about the medications I take to manage possible drug interactions or to provide instructions and requirements to my pharmacy to order JINARC. I understand that the information shared between my pharmacy and the Programme will only pertain to my treatment with JINARC and participation in the Programme.

I understand that this PPAF is not applicable for any treatment other than JINARC and that Otsuka reserves the right to terminate the Programme, or any aspect thereof, at any time, in its sole discretion, without prior notice.